ABSCINT

𝗥𝗲𝗳𝗹𝗲𝗰𝘁𝗶𝗻𝗴 𝗼𝗻 𝗮 𝗕𝘂𝘀𝘆 𝗮𝗻𝗱 𝗦𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹 𝗬𝗲𝗮𝗿 𝗮𝘁 𝗔𝗕𝗦𝗖𝗜𝗡𝗧 As we continue our week of reflection and gratitude, today we turn the spotlight on the companies that have been instrumental in providing support for our 𝗣𝗵𝗮𝘀𝗲 2𝗕 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹 (HERMIA trial). This pivotal study has been a major focus for us at ABSCINT in the past year, and it simply wouldn't be possible without the outstanding logistical and expertise support of our trusted partners: 🌐 ECSOR sa/nv, ❄️Raes Pharmaceutical Logistics, 📷 Orilab,⚛️ BIP and🚚 ISI. To all of you, we extend our gratitude. Your professionalism, precision, and dedication have facilitated our clinical development journey. Here’s to continuing our successful collaboration in the year ahead! 🌟 #ABSCINT #Gratitude #Collaboration #ClinicalTrials #HERMIAtrial

𝗥𝗲𝗳𝗹𝗲𝗰𝘁𝗶𝗻𝗴 𝗼𝗻 𝗮 𝗕𝘂𝘀𝘆 𝗮𝗻𝗱 𝗦𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹 𝗬𝗲𝗮𝗿 𝗮𝘁 𝗔𝗕𝗦𝗖𝗜𝗡𝗧 Just as we did yesterday, today we want to take a moment to reflect on the incredible milestones we achieved this year at ABSCINT. One of the highlights was the initiation of our 𝗣𝗵𝗮𝘀𝗲 2𝗕 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹 – a significant step forward in our journey. Of course, such progress wouldn’t be possible without having GMP-compliant product in place. That’s why today, we want to shine a spotlight on two key partners who made this possible: Xpress Biologics now part of Sartorius and Trasis. Your expertise, support, and dedication have been important in helping us generate our clinical results. Thank you for being part of our journey and for you contribution in this success. Here’s to continued collaboration and achievements ahead! 🌟

As the year draws to a close, Abscint would like to take a moment to reflect on the past year. We are incredibly proud of what we have achieved in 2024! Of course, we wouldn’t be where we are today without the support of many.  Today, we want to extend our special thanks to LegiaPark and EEBIC. We are truly fortunate to have two wonderful workplaces. At EEBIC, we regularly meet to discuss our clinical activities. It’s a pleasure to have an office so close to UZ Brussel, Bordet, and our other clinical sites.  Equally, we love working at LegiaPark in Liège, where we’re surrounded by other key players in nuclear medicine. It’s the perfect base for brainstorming and exchanging ideas with our colleagues from companies active in this exciting field.  A heartfelt thank you to the teams at EEBIC and LegiaPark for making us feel at home and supporting us in our journey. Here’s to continued collaboration in the years to come!

🎁✨ Sinterklaas Has Already Visited ABSCINT! 🎅🎁 At ABSCINT, we've already had a visit from Sinterklaas to celebrate the hard work and dedication of our amazing team. 🎉 Whether it's solving challenges, lighting up new ideas, or just going the extra mile, everyone here has truly earned a moment of recognition. But now the big question looms: will Santa Claus also make his way to ABSCINT? 🤔🎅 With such a hardworking group, he might just have to stop by and leave a little extra under the tree! Wishing you all a wonderful and festive December. 🌟❄️ #ABSCINT #HolidaySeason #Teamwork #Sinterklaas

📰 𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗡𝗲𝘄𝘀 𝗳𝗼𝗿 𝗔𝗕𝗦𝗖𝗜𝗡𝗧! 📰 On a sunny morning in Liège, we received an eagerly awaited letter from 𝗦𝗣𝗪 𝗥𝗲𝗰𝗵𝗲𝗿𝗰𝗵𝗲 (Public Service of Wallonia). The letter delivered fantastic news: the approval of support for our work in developing an innovative 𝗶𝗻-𝘃𝗶𝘃𝗼 𝗶𝗺𝗮𝗴𝗶𝗻𝗴 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗳𝗼𝗿 𝗛𝗘𝗥𝟮 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗶𝗻 𝗰𝗮𝗻𝗰𝗲𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀. This support represents more than just financial aid—it reflects the Walloon Region’s commitment to transforming innovation into real-world impact for patients. For ABSCINT, it marks a significant milestone, reinforcing our determination to advance molecular imaging solutions that make a difference for those in need. 🙏 𝗧𝗵𝗮𝗻𝗸 𝘆𝗼𝘂, 𝗦𝗣𝗪 𝗥𝗲𝗰𝗵𝗲𝗿𝗰𝗵𝗲, 𝗳𝗼𝗿 𝗯𝗲𝗹𝗶𝗲𝘃𝗶𝗻𝗴 𝗶𝗻 𝗼𝘂𝗿 𝗺𝗶𝘀𝘀𝗶𝗼𝗻 and empowering us to work toward a future where precision diagnostics lead to better care for cancer patients. Let’s keep moving forward—driven by science, inspired by hope, and committed to making an impact. 💡💪 #Gratitude #Innovation #MolecularImaging #HER2Detection 

We’re proud to announce that ABSCINT is a sponsor at the upcoming European Association of Nuclear Medicine (EANM) Focus Meeting! 🎉      Taking place from January 30 to February 1, 2025, in beautiful Malta, this focus meeting centers on shaping the future of breast cancer care with Molecular Imaging.   At ABSCINT, we are deeply committed to advancing molecular imaging and believe that our innovative HER2 PET tracer has the potential to contribute to this mission.                                                                                                                                             We look forward to engaging with leading experts in the field, exchanging ideas, and being inspired by the talks on the program. It’s a privilege to support this event and contribute to the future of nuclear medicine. If you want to meet our Clinical Operations and Medical Affairs Lead, Dieter Frijns and our CEO, Karine Clauwaert, please reach out as they both will participate!      #EANM #MolecularImaging #BreastCancerCare #Innovation #ABSCINT

🌟 Exciting Visit to the University of Liège! 🌟 Earlier this week, our CEO Karine Clauwaert, had the pleasure of visiting the University of Liège. Navigating the ULG campus proved to be quite the adventure—if you've been there, you know it's a bit of a maze! 🗺️ But after some wandering and a few moments of "Where are you?" they found each other and kicked off a great meeting. The topic of discussion? 🧬 Camelid single-domain antibodies! Neptuns, just like ABSCINT, is focused on these remarkable molecules. It was a joy to connect with the ULG team, who share the same enthusiasm for their potential. The mutual exchange of ideas and expertise made for a truly inspiring meeting. We’re excited about the possibilities and possible collaborations ahead—together, pushing the boundaries of science and innovation. #Collaboration #Innovation #Neptuns #ULG #SingleDomainAntibodies #ResearchAndDevelopment

As a company we are indeed delighted to have our main office at LégiaPark. Not only does it offer modern, state-of-the-art infrastructure, but it also houses companies mainly active in life sciences and biotechnology. Coupled with the vibrant nuclear medicine community in the region, LégiaPark is the perfect base camp for ABSCINT to thrive, innovate and contribute to the future of molecular PET imaging.

🌟 Unlocking the Future of Molecular PET Imaging with Single-Domain Antibodies 🌟 In the field of molecular imaging, the choice of tracer is critical for rapid, accurate and safe diagnosis. Single-domain antibodies (sdAbs) are transforming PET imaging by addressing some of the key limitations of traditional antibodies. Here’s why sdAbs stand out: 1️⃣ Faster Imaging Times: Unlike conventional antibodies, which requires waiting 3-5 days after injection to deliver optimal images, sdAbs enable high-quality imaging just 1.5 hours post-injection. This accelerated timeline not only improves patient experience but also enhances workflow efficiency for healthcare teams. 2️⃣ Lower Radiation Exposure: sdAbs have a short biological half-life (order of several tens of minutes) in the body, which limits patient exposure to radioactive tracers. This is a critical advantage, especially for repeat imaging, allowing for safer diagnostic procedures. 3️⃣ Ease of Production: Compared to larger antibodies, sdAbs are easier and more cost-effective to produce. They can be manufactured in lower organisms such as P.pichia and E.coli, making them cheaper to produce. 4️⃣ Better Tissue Penetration: Due to their smaller size (~10x smaller compared to conventional antibodies), sdAbs exhibit enhanced tissue penetration and rapid clearance from non-target tissues. This can result in clearer images with less background noise, improving diagnostic accuracy. Within ABSCINT we aim to use these advantages to the fullest and generate promising advancements in molecular PET imaging—offering quicker, safer, and more accessible diagnostics without compromising on target specificity. Exciting times ahead for both clinicians and patients! 💡 #MolecularImaging #PETImaging #SingleDomainAntibodies #Diagnostics #HealthcareInnovation 

To Cold Kit or Not to Cold Kit? That Is the Question! After thorough internal discussions and consultations with many Key Opinion Leaders, we are even more strengthened in our vision that developing a cold kit for our HER2 molecular imaging product is the way forward. Why a cold kit? The benefits are clear: 🔹 𝗦𝗶𝗺𝗽𝗹𝗶𝗳𝗶𝗲𝗱 𝗪𝗼𝗿𝗸𝗳𝗹𝗼𝘄: With a cold kit, radiopharmacies can prepare doses quickly and efficiently, saving time and reducing complexity. 🔹 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗔𝗰𝗰𝗲𝘀𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝘆: Cold kits enable broader distribution, allowing more healthcare providers to access cutting-edge in-vivo imaging solutions. 🔹 𝗜𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝗖𝗼𝘀𝘁-𝗘𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲𝗻𝗲𝘀𝘀 𝗳𝗼𝗿 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘀𝗶𝘁𝗲𝘀: providing sterile Drug products to the clinical centres reduces the need for specialized infrastructure, making high-quality imaging more affordable. 🔹 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗘𝗮𝘀𝗲: Streamlined production and standardized procedures support smoother regulatory approvals worldwide. we are excited to bring this innovation to the field of HER2 imaging, facilitation product access and advancing precision medicine. Stay tuned for updates as we progress! #Innovation #InVivoImaging #HER2 #ColdKit #PrecisionMedicine